Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma

Shankar, Ananth; Pinkerton, CR; Atra, Ayad; Ashley, S.; Lewis, Ian; Spooner, D.; Cannon, Stephen R.; Grimer, R. J.; Cotterill, SJ; Craft, Alan

doi:10.1016/s0959-8049(99)00144-6

Cited by 94 publications

(56 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding expands on previous reports that patients who have late recurrences may have better outcomes. 4,6,14,17 We also found that the site of recurrence was significant, confirming the recent observation of Shankar et al 4 that simultaneous local and distant recurrences signify more aggressive disease, with earlier tumor recurrence and poorer outcome.…”

Section: Discussionsupporting

confidence: 90%

“…[1][2][3][4] During the earlier years of multimodal therapy, approximately 25% of all patients experienced local treatment failure, and another 20 -40% experienced distant treatment failure. [5][6][7][8][9][10] Although improved local control therapy and the development of new and more intensive chemotherapy combinations have reduced the frequency of local recurrence, a large proportion of patients with ET continue to experience recurrence.…”

mentioning

confidence: 99%

“…[5][6][7][8][9][10] Although improved local control therapy and the development of new and more intensive chemotherapy combinations have reduced the frequency of local recurrence, a large proportion of patients with ET continue to experience recurrence. [1][2][3][4]11 The likelihood of long-term survival after recurrence of ET is less than 20 -25%. [11][12][13] Although the salvage therapies used for these patients have not been described in detail, the apparent better outcomes associated with local or late recurrence 12,14 suggest the exis-tence of subgroups of patients with different prognoses.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Survival after recurrence of Ewing Tumors

Rodríguez‐Galindo¹,

Billups²,

Kun³

et al. 2002

Cancer

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Survival after recurrence of Ewing Tumors

Rodríguez‐Galindo¹,

Billups²,

Kun³

et al. 2002

Cancer

View full text Add to dashboard Cite

“…Although some studies demonstrated no significant differences in the rates of local recurrence and/or survival between patients who received radiotherapy alone and patients who underwent surgery, 9,26,33 other studies demonstrated that surgery improved clinical outcomes significantly. 34,35 Results from 1058 patients who were treated on Cooperative Ewing Sarcoma Study 81 (CESS 81), CESS 86, and European Intergroup Cooperative Ewing Sarcoma Study 92 demonstrated that local control and EFS among patients who received definitive radiotherapy was significantly lower than EFS among patients who underwent surgery with or without receiving additional radiotherapy, although the former subgroup of patients represented a negatively selected population with unfavorable tumor sites.…”

Section: Discussionmentioning

confidence: 99%

Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan

Obata

Ueda

Kawai

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND.Ewing sarcoma family of tumors (ESFT) of bone is extremely rare in Japan. The objectives of the current study were to assess the clinical outcome and prognostic factors of patients with ESFT of bone in Japan and to compare them between Euro‐American and Japanese populations.METHODS.The authors conducted a retrospective analysis of 243 patients who were treated for ESFT of bone in Japan between 1981 and 2003. Local therapy was surgery in 35% of patients, surgery combined with radiotherapy in 40% of patients, radiotherapy alone in 22% of patients, and no local treatment in 3% of patients. All but 3 patients received various regimens of multidrug chemotherapy.RESULTS.The median patient age was 16 years. The primary disease sites were the trunk in 53% of patients and the extremities in 47% of patients. Forty‐one patients had metastases at presentation. The median follow‐up was 66 months. A univariate survival analysis demonstrated that patients who had metastases at presentation, primary site in the trunk, age ≥16 years, tumor size ≥10 cm, tumor that responded poorly to induction chemotherapy, and local treatment with radiotherapy alone had a significantly worse event‐free survival (EFS). A multivariate analysis further verified that the former 3 factors were significant adverse prognostic factors. Of 201 patients with localized disease, 45 patients who received current chemotherapy regimens that included ifosfamide and etoposide had a significantly better 5‐year EFS rate (67.6%) compared with other patients.CONCLUSIONS.The clinical outcome of patients with localized ESFT of bone in Japan has improved markedly with the use of current chemotherapy regimens that include ifosfamide and etoposide and has become comparable to the outcomes observed in other major series of Euro‐American patients. The prognostic factors are also almost identical. Cancer 2007 © 2007 American Cancer Society.

show abstract

“…5,[22][23][24] Various studies investigating clinical variables predictive of survival in Ewing tumor 6,25-27 have identified tumor site, tumor volume, age, sex, and histological response to chemotherapy. The most relevant risk factor is primary dissemination, 4,11,28,29 especially bone metastases at the time of diagnosis.…”

Section: Local Therapy Disseminated Ewing Sarcoma/haeusler Et Almentioning

confidence: 99%

The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES)

Haeusler

Ranft

Boelling

et al. 2009

Cancer

147

124

View full text Add to dashboard Cite

BACKGROUND:The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES) was investigated.METHODS:We analyzed 120 patients registered into the European Ewing Tumor Working Initiative of National Groups (EURO‐E.W.I.N.G. 99) trial at the trial center of Muenster from 1998 to 2006. Median age was 16.2 years. Local treatment of the primary tumor was surgery in 26 of 120 patients, surgery and radiotherapy in 21 patients, and definitive radiotherapy in 40 patients. For treatment of metastases, 6 of 120 patients received surgery; 9 patients, surgery and radiotherapy; and 33 patients, definitive radiotherapy. Forty‐seven (39%) patients had local treatment of both the primary tumor and metastases, 41 (34%) patients of either the primary tumor or metastases, and 32 (27%) received no local therapy.RESULTS:Event‐free survival (EFS) at 3 years was 0.24 (95% CI, 0.16‐0.33). Univariate analyses demonstrated the impact of local therapy given to the primary tumor: 3‐year EFS was 0.25 with surgery, 0.47 with surgery and radiotherapy, 0.23 with radiotherapy, and 0.13 when no local therapy was administered (P < .001). Three‐year EFS in PDMES was also influenced by the local treatment: surgery, 0.33; surgery and radiotherapy, 0.56; radiotherapy, 0.35; no local therapy, 0.16 (P = .003). Three‐year EFS was 0.39 in patients who received local treatment of both primary tumor and PDMES, compared with 0.17 in patients with any local treatment of either primary tumor or PDMES and 0.14 in patients with no local therapy (P < .001). Multivariate analysis showed absence of local treatment to be the major risk factor (HR = 2.21; P = .027; n = 20).CONCLUSIONS:Local therapy of involved sites is important for patients with PDMES and should complement systemic treatment whenever possible. Cancer 2010. © 2010 American Cancer Society.

show abstract

Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma

Cited by 94 publications

References 35 publications

Survival after recurrence of Ewing Tumors

Survival after recurrence of Ewing Tumors

Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan

The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES)

Contact Info

Product

Resources

About